December 1, 2016 - By Hazel Jackson · 0 Comments
The stock of Dimension Therapeutics Incorporated (NASDAQ:DMTX) registered an increase of 2.6% in short interest. DMTX’s total short interest was 366,700 shares in December as published by FINRA. Its up 2.6% from 357,400 shares, reported previously. With 64,000 shares average volume, it will take short sellers 6 days to cover their DMTX’s short positions. The short interest to Dimension Therapeutics Incorporated’s float is 2.53%. About 7,342 shares traded hands. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 44.37% since April 28, 2016 and is downtrending. It has underperformed by 50.30% the S&P500.
Dimension Therapeutics, Inc. is a gene therapy company. The company has a market cap of $110.19 million. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It currently has negative earnings. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase deficiency, and glycogen storage disease type Ia (GSDIa).
Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Buy” rating by Goldman Sachs on Monday, November 16. The firm earned “Buy” rating on Monday, November 16 by Citigroup. Roth Capital initiated the shares of DMTX in a report on Friday, November 6 with “Buy” rating. Cantor Fitzgerald initiated the stock with “Buy” rating in Thursday, February 18 report. The company was initiated on Monday, November 16 by Canaccord Genuity. The rating was initiated by Cantor Fitzgerald on Friday, June 3 with “Buy”. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) earned “Outperform” rating by Wells Fargo on Friday, December 4. The firm has “Buy” rating by Goldman Sachs given on Friday, December 4.
Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.
More recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Marketwatch.com which released: “Dimension Therapeutics Inc.” on July 22, 2014. Also Wsj.com published the news titled: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” on October 22, 2015. Streetinsider.com‘s news article titled: “Dimension Therapeutics (DMTX) Receives Positive EMA CHMP Opinoin for DTX401 as …” with publication date: November 29, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson